Issue Date: October 8, 2012
Celgene Signs Two Cancer Drug Pacts
Celgene will pay $35 million to fund R&D on VentiRx Pharmaceuticals’ VTX-2337, a small-molecule Toll-like receptor 8 agonist being developed as a cancer immunotherapy. During an option period, Celgene will have an exclusive right to acquire the Seattle-based firm. Separately, Celgene will work with the Leukemia & Lymphoma Society to identify and fund promising blood cancer research projects. The pact is the first in a new LLS program of venture philanthropy projects with the drug industry.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society